Free Trial
→ The Executive Order That Quietly Changed What Your Dollar Means (From Reagan Gold Group) (Ad)tc pixel
NASDAQ:MRNA

Moderna Q3 2026 Earnings Date & Estimates

Moderna logo
$197.00 +0.52 (+0.26%)
Closing price 10/8/2026 04:00 PM Eastern
Extended Trading
$195.82 -1.19 (-0.60%)
As of 10/8/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moderna is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for 8:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Moderna in Q3 2026

Moderna is expected to post earnings of -$1.10 per share on revenue of $895.85 million. In the same quarter a year earlier Moderna reported -$0.51 per share on revenue of $1.02 billion. Moderna last reported on July 31, 2026, posting -$1.97 per share and beating the -$2.03 consensus estimate. Moderna has beaten the consensus EPS estimate in 7 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$1.10
Expected Revenue
$895.85 million
Prior-Year EPS
-$0.51
Prior-Year Revenue
$1.02 billion
Expected Revenue Growth
-11.8%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$1.97 (Beat by +$0.06)
Last Quarter Revenue
$145.00 million
EPS Beat Rate
7 of last 8 quarters

Prepare for the Q3 2026 Call

Moderna Q3 2026 Earnings FAQ

Moderna (NASDAQ:MRNA) is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens.

Moderna's Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Moderna to post earnings of -$1.10 per share for Q3 2026.

The consensus revenue estimate for Moderna is $895.85 million for Q3 2026.

Moderna Earnings Headlines

Biotech Stocks To Follow Now - October 7th
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31101213
Moderna (MRNA) Gets a Hold from Morgan Stanley
October 8 at 4:48 PM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/MRNA/pressreleases/5070794/moderna-mrna-gets-a-hold-from-morgan-stanley/
The Executive Order That Quietly Changed What Your Dollar Means
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
 |  Reagan Gold Group (Ad)
Moderna's Nasdaq-100 Entry: What Does It Mean for the Stock?
October 8 at 11:48 AM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/modernas-nasdaq-100-entry-does-114200473.html
Company News for Oct 8, 2026
October 8 at 6:47 AM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/company-news-oct-8-2026-082300220.html
Health rounds: Experimental approach uses AI to eliminate cold storage for mRNA vaccines
October 7 at 11:01 PM  |  msn.comhttps://www.msn.com/en-us/news/other/health-rounds-experimental-approach-uses-ai-to-eliminate-cold-storage-for-mrna-vaccines/ar-AA2dJEPi
See More Moderna Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Moderna? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Moderna and other key companies, straight to your email.

About Moderna

Moderna (NASDAQ:MRNA) is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease, supporting the company’s work across infectious diseases, immuno-oncology, rare diseases, autoimmune conditions, and cardiovascular diseases.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults. The company also maintains a development pipeline focused on additional respiratory vaccines, combination vaccines, cancer therapies, and other treatments based on its mRNA platform.

Founded in 2010 and headquartered in Cambridge, Massachusetts, Moderna serves markets internationally through regulatory approvals, commercial operations, and collaborations. Stéphane Bancel has served as the company’s chief executive officer since 2011, while Noubar Afeyan, one of Moderna’s founders, serves as executive chairman.

View Moderna Profile
Earnings Tools